ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
ImmunityBio, Inc. shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume.
Eli Lilly stock slips after hours as obesity-pill race stays in the spotlight
Eli Lilly and Company shares dropped 2.1% on Friday, closing near $1,064.29 in after-hours trading. During the session, the stock swung between $1,094.57 and $1,063.25.
Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares
Shares of Boston Scientific Corp climbed roughly 3.1% to $90.77 on Tuesday, clawing back some of last week’s losses. Investors digested new clinical data amid ongoing concerns over regulatory issues and deal rumors.
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade
Eli Lilly and Company shares drew attention heading into Tuesday’s U.S. session, following a Friday close in the green. Investors digested new developments in the obesity-drug sector, a key driver behind the drugmaker’s recent surge.
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line
ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20.
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk
Costco Wholesale Canada told customers who bought certain Peace by Chocolate gift boxes online to stop eating two pistachio-containing chocolates, after an ingredient supplier triggered a warning over possible Salmonella contamination. The “voluntary, precautionary” recall covers Our Classic Box – 15 assorted filled chocolates and The Harmony Bar included in Peace by Chocolate Small and Medium Bestsellers Boxes purchased on Costco.ca between Sept. 7 and Dec. 3, the notice showed.
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes
Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight
Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14.
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market
Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public
Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight
Merck & Co shares dipped in late trading on Monday after U.S. health officials rewrote the childhood and adolescent immunization schedule, including a change to a one-dose recommendation for the human papillomavirus vaccine. Merck closed up 0.93% at $107.44 and was last down 0.22% at $107.20 after the bell. Yahoo Finance
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing
Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next
Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener
Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Britain’s Tesco has recalled three 170-gram own-brand pate products after they were labelled with an incorrect use-by date, prompting a warning over a possible microbiological risk, the UK’s Food Standards Agency said on Jan. 3. The recall covers Tesco Coarse Farmhouse Pate, Coarse Ardennes Pate and Smooth Chicken Liver Pate with a use-by date of 05 January 2026. Food Standards Agency
Bupa renews ParalympicsGB partnership and seals Nuffield Health deal as robotic knee surgery hits 1,000 mark
Bupa UK on Wednesday renewed its role as Official Healthcare Partner of ParalympicsGB and agreed a new three-year contract between Bupa UK Insurance and Nuffield Health, the company said. The Nuffield agreement adds direct appointment booking and wider access to diagnostics for Bupa customers.
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation
Axsome Therapeutics, Inc. shares jumped 22.9% to $182.64 in after-hours trading on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental New Drug Application for AXS-05 to treat agitation linked to Alzheimer’s disease and granted it Priority Review. The agency set an April 30, 2026 target action date, and CEO Herriot Tabuteau said “up to 76% of people with Alzheimer’s disease experience agitation.” GlobeNewswire
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next
Structure Therapeutics Inc. is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates.
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown
On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1
So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)
December 17, 2025 — If you keep dairy-free frozen treats stocked for the holidays, it’s worth taking a quick look in your freezer. Danone U.S. has issued a voluntary nationwide recall for specific pints of So Delicious Dairy Free Salted Caramel Cluster after the company warned the product may contain foreign materials — including small stones and other hard objects — in the cashew pieces mixed into the dessert. U.S. Food and Drug Administration+1
California Vega Farms Egg Recall: 63 Sick, 13 Hospitalized in Salmonella Outbreak—How to Identify Affected Eggs
SACRAMENTO, Calif. — A Salmonella Enteritidis outbreak in California has been linked to recalled Vega Farms in-shell brown eggs, with state health officials reporting 63 illnesses and 13 hospitalizations tied to the outbreak strain as of Dec. 5, according to the California Department of Public Health. California Department of Public Health
Vega Farms Egg Recall Update: California Links Salmonella Outbreak to Dixon Farm Eggs; 63 Sick, 13 Hospitalized
SACRAMENTO, Calif. — California health officials are urging residents and businesses across parts of Northern California to stop eating, selling, or serving certain Vega Farms in-shell eggs after the products were linked to a Salmonella Enteritidis outbreak that has already sickened dozens of people. California Department of Public Health+1